Streamlining T-cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine

DeVorkin L, et al. Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 2022

This poster describes a large panel of fully human CD3-binding antibodies discovered using integrated antibody discovery, characterization, and engineering technologies. Antibody binding assessments show key species cross-reactivity and binding epitopes distinct from commonly used parental antibodies, including SP34–2. In a second discovery campaign designed to enhance the number of cross-reactive antibodies, hundreds of additional unique antibody sequences were identified. Finally, in proof-of-concept experiments, the OrthoMab™ bispecifics platform was used to generate potent EGFR x CD3 T-cell engagers that maintain low levels of cytokine production.

DOI: 10.1136/jitc-2022-SITC2022.1196

Further reading:

1. Bergqvist P, et al. J Immunother Cancer 2024;12(Suppl 2):A1–A1683.
2. Mai M, et al. Cancer Res (2024) 84 (6_Supplement): 1868.
3. Mai M, et al. J Immunother Cancer 2023;11(Suppl 1):A1–A1731.
4. Mai M, et al. Cancer Res (2023) 83 (7_Supplement): 1886.
5. DeVorkin L, et al. Cancer Res (2022) 82 (12_Supplement): 312.